SOURCE: OmniComm Systems, Inc.

July 07, 2008 09:16 ET

OmniComm Systems, Inc. Has Another Record Breaking Quarter Delivering Electronic Data Capture (EDC) Solutions & Services

$8.7 Million in Contracts Are Signed in Q2 2008, Representing a 300% Increase From Q2 Last Year

FT. LAUDERDALE, FL--(Marketwire - July 7, 2008) - OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture solutions for clinical trials, today announced another landmark quarter for new business. This is the 3rd quarter in a row that OmniComm has surpassed its previous best quarter. Signed contracts through the first 2 quarters of 2008, totaling almost $12M, have already surpassed signed contracts from all of last year.

The second quarter of 2008 was bolstered by a long-term guaranteed contract with a major biotechnology company. OmniComm also added seven new clients to its customer list, added five more trials from repeat customers and added six new partners to its very successful Preferred Partnership Programs.

"I couldn't be happier with the current momentum and speed in which we continue to grow," said Stephen Johnson, COO of OmniComm. "We are extremely hot right now and I don't see any signs of us slowing down. Our pipeline is stronger than ever and we are coming off one of our best trade shows to date at the recent DIA in Boston. We have grown from 47 to 83 people in the last year alone and we continue to hire industry experienced individuals, something that I think that is lacking in other EDC companies. Our recipe for success is simple -- we offer the best products and services at the best price and we smother our customers with close, personal attention."

OmniComm continues to increase its customer base with a strong mix of new customer business coupled with steady, recurring business from its existing loyal customers. The following is a breakdown of new business for Q2 2008.

Q2 New Contracts 2008:

Pharmaceutical
-- 12 month, Phase II, pain study with 1 site and 120 subjects
-- 39 month, Phase II, multiple sclerosis study with 60 sites and
   350 subjects
Biotechnology
-- 5 Year Enterprise Agreement (including 5 studies in Q2)
     -- 14 month, Phase IB, HIV study with 12 sites and 24 subjects
     -- 3 month, Phase I/II, HIV study with 1 site and 18 subjects
     -- 17 month, Phase II, hepatitis study with 50 sites and 110 subjects
     -- 4 month, Phase IV, HIV study with 30 sites and 160 subjects
     -- 5 month, Phase I, hepatitis study with 1 site and 40 subjects
Contract Research Organizations
-- 10 month, Phase I, oncology study with 5 sites and 80 subjects
-- 1 month, device, mammography study with 1 site and 100 subjects
-- 15 month, Phase II, renal failure study with 2 sites and 150 subjects
-- 10 month, Phase IV, urinary incontinence study with 100 sites and
   500 subjects
-- 7 month, Phase III, oncology study with 30 sites and 350 subjects
Medical Device
-- 4 month, Phase IV, cardiology study with 1 site and 500 subjects
Academic
-- 1 month consulting project

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Contact Information

  • CONTACT:
    Lizanne Kelley
    OmniComm Systems, Inc.
    954-473-1254 Extension 283
    Email Contact